Trials / Completed
CompletedNCT01130584
Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- —
- Sponsor
- National University Hospital, Singapore · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer. Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Pyruvate kinase isoform M2 |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2010-05-26
- Last updated
- 2013-12-11
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT01130584. Inclusion in this directory is not an endorsement.